In Brief: Atrion
This article was originally published in The Gray Sheet
Atrion: Diversified medical products manufacturer plans to acquire for $24.5 mil. cash certain assets related to the cardiovascular and specialized intravenous fluid delivery product lines of Quest Medical under a definitive agreement announced Dec. 30. Products to be acquired include a myocardial protection system for cardioplegia delivery during open-heart surgery; specialized pressure control valves; pre-bypass and arterial line filters; bubble traps used by perfusionists during cardiopulmonary bypass surgery; and over 50 intravenous fluid delivery products. The devices would add about $14.5 mil. in annual sales to Atrion's current revenues of about $30 mil. per year. Under the terms of the deal, Atrion will lease for one year Quest's Allen, Texas manufacturing facility and will have an option to buy the facility for an additional $6.5 mil. The acquisition, which has been approved by the boards of directors of both companies, is anticipated to be completed in late January...
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.